Department of Environmental Health Sciences, School of Public Health and Tropical Medicine, Tulane University, 1440 Canal Street, Suite 2100, New Orleans, Louisiana 70112, USA.
Chem Res Toxicol. 2009 Dec;22(12):1975-83. doi: 10.1021/tx900270z.
4,4'-Methylenediphenyl diisocyanate (MDI) is the most important of the isocyanates used as intermediates in the chemical industry. Among the main types of damage after exposure to low levels of MDI are lung sensitization and asthma. Albumin adducts of MDI might be involved in the etiology of sensitization reactions. It is, therefore, necessary to have sensitive and specific methods for monitoring the isocyanate exposure of workers. To date, urinary metabolites or protein adducts have been used as biomarkers in workers exposed to MDI. However, with these methods it is not possible to determine whether the biomarkers result from exposure to MDI or to the parent aromatic amine 4,4'-methylenedianiline (MDA). This work presents a procedure for the determination of isocyanate-specific albumin adducts. In a long-term experiment, designed to determine the carcinogenic and toxic effects of MDI, rats were exposed chronically for 3 months, to 0.0 (control), 0.26, 0.70, and 2.06 mg MDI/m(3) as aerosols. Albumin was isolated from plasma, digested with Pronase E, and analyzed by LC-MS/MS. MDI formed adducts with lysine: N(6)-[({4-[4-aminobenzyl]phenyl}amino)carbonyl]lysine (MDI-Lys) and N(6)-[({4-[4-(acetylamino)benzyl]phenyl}amino)carbonyl] lysine (AcMDI-Lys). For the quantitation of the adducts in vivo, isotope dilution mass spectrometry was used to measure the adducts in 2 mg of albumin. The adducts found in vivo (MDI-Lys and AcMDI-Lys) and the corresponding isotope labeled compounds (MDI-[(13)C(6)(15)N(2)]Lys and Ac[(2)H(4)]MDI-Lys) were synthesized and used for quantitation. The MDI-Lys levels increased from 0-24.8 pmol/mg albumin, and the AcMDI-Lys levels increased from 0-1.85 pmol/mg albumin. The mean ratio of MDI-Lys/AcMDI-Lys for each dose level was greater than >20. The albumin adducts correlate with other biomarkers measured in the same rats in the past: urinary metabolites and hemoglobin adducts released after mild base hydrolysis. This method will enable one to measure isocyanate-specific albumin adducts in workers. This new biomonitoring procedure will allow for the assessment of suspected exposure sources and may contribute to the identification of individuals who are particularly vulnerable for developing bronchial asthma and other respiratory diseases after exposure to isocyanates. In addition, it will help to improve the production of antigens for the analysis of antibodies in exposed workers.
4,4'-亚甲基二苯基二异氰酸酯(MDI)是用作化学工业中间体的异氰酸酯中最重要的一种。在接触低水平 MDI 后,主要的损害类型是肺部致敏和哮喘。MDI 的白蛋白加合物可能参与致敏反应的病因。因此,有必要开发敏感和特异的方法来监测工人的异氰酸酯暴露情况。迄今为止,尿代谢物或蛋白质加合物已被用作接触 MDI 的工人的生物标志物。然而,使用这些方法无法确定生物标志物是由于接触 MDI 还是母体芳香胺 4,4'-亚甲基二苯胺(MDA)引起的。本工作提出了一种测定异氰酸酯特异性白蛋白加合物的方法。在一项旨在确定 MDI 的致癌和毒性作用的长期实验中,大鼠以气溶胶形式连续 3 个月暴露于 0.0(对照)、0.26、0.70 和 2.06 mg MDI/m(3)。从血浆中分离白蛋白,用 Pronase E 消化,并通过 LC-MS/MS 分析。MDI 与赖氨酸形成加合物:N(6)-[({4-[4-氨基苄基]苯基}氨基)羰基]赖氨酸(MDI-Lys)和 N(6)-[({4-[4-(乙酰氨基)苄基]苯基}氨基)羰基]赖氨酸(AcMDI-Lys)。为了定量体内的加合物,使用同位素稀释质谱法测量了 2mg 白蛋白中的加合物。在体内发现的加合物(MDI-Lys 和 AcMDI-Lys)和相应的同位素标记化合物(MDI-[(13)C(6)(15)N(2)]Lys 和 Ac[(2)H(4)]MDI-Lys)被合成并用于定量。MDI-Lys 水平从 0-24.8 pmol/mg 白蛋白增加,AcMDI-Lys 水平从 0-1.85 pmol/mg 白蛋白增加。每个剂量水平的 MDI-Lys/AcMDI-Lys 比值均大于>20。白蛋白加合物与过去在相同大鼠中测量的其他生物标志物相关:尿代谢物和轻度碱水解后释放的血红蛋白加合物。该方法将使人们能够测量工人的异氰酸酯特异性白蛋白加合物。这种新的生物监测程序将能够评估可疑的暴露源,并有助于确定在接触异氰酸酯后易患支气管哮喘和其他呼吸道疾病的个体。此外,它将有助于改善用于分析暴露工人抗体的抗原的生产。